恩替卡韦治疗慢性乙型肝炎初治患者的临床效果

Clinical Effect of Entecavir in the Initial Treatment of Patients with Chronic Hepatitis B

目的探究恩替卡韦治疗慢性乙型肝炎初治患者的临床效果.方法选取2016年8月至2018年8月盐城市第一人民医院南通大学第四附属医院收治的102例慢性乙型肝炎患者作为观察对象,电脑便利抽样将患者随机分为对照组(复方甘草酸苷注射治疗)和观察组(复方甘草酸苷注射治疗+恩替卡韦分散片),各51例.比较两组患者治疗前后乙肝病毒的脱氧核糖核酸(HBV-DNA)水平及治疗后4、8、12、24及48周后患者乙型肝炎e抗原(HBeAg)转阴率及血清转换率、HBV-DNA转阴率及不良反应率.结果从治疗8周开始,观察组患者HBV-DNA水平明显低于对照组,HBV-DNA转阴率明显高于对照组(P<0.05);从12周开始,观察组患者HBeAg转阴率及HBeAg血清转换率均显著高于对照组(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05).结论恩替卡韦治疗慢性乙型肝炎初治患者,能够使患者HBV-DNA水平迅速降低,提高患者HBeAg转阴率、HBeAg血清转换率及HBV-DNA转阴率,且具有较高的安全性.

Objective To explore the clinical effect of entecavir in the initial treatment of patients with chronic hepatitis B(CHB).Methods A total of 102 patients with CHB admitted to the Fourth Affiliated Hospital of Nantong University,the First People's Hospital of Yancheng City from August 2016 to August 2018 were selected as the subjects.The patients were randomly divided into a control group(compound glycyrrhizin injection)and an observation group(compound glycyrrhizin injection+entecavir dispersible tablet),with 51 cases in each group.The HBV-DNA levels before and after treatment,as well as HBeAg negative conversion rates,HBeAg serum conversion rates,HBV-DNA negative conversion rates and adverse reaction incidences after 4,8,12,24 and 48 weeks of treatment were compared between the two groups.Results Compared with the control group,the HBV-DNA levels in the observation group were significantly decreased and HBV-DNA negative conversion rates were significantly increased from 8 weeks of treatment(P<0.05);the HBeAg negative conversion rates and serum conversion rates were significantly increased from 12 weeks of treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Entecavir can decrease the level of HBV-DNA in patients with CHB,increase the negative rate of HBeAg,serum conversion rate of HBeAg and negative rate of HBV-DNA,and had a high safety.